EurekaMag
+ Translate
+ Most Popular
Gaucher's disease;thirty-two years experience at Siriraj Hospital
A study of Macrobathra Meyrick from China (Lepidoptera, Cosmopterigidae)
First occurrence in ores of tetragonal chalcocite
Effects of trace element nutrition on sleep patterns in adult women
N.Z. range management guidelines. 2. Design of grazing management systems for tussock country
A case of lipoma of the esophagus
A revision of world Acanthosomatidae (Heteroptera: Pentatomidae): keys to and descriptions of subfamilies, tribes and genera, with designation of types
Life history of the coronate scyphozoan Linuche unguiculata (Swartz, 1788)
Perceptual restoration of obliterated sounds
Mutagenicity studies on two chromium(III) coordination compounds
The formation of the skeleton. I. Growth of a long bone. 1st appearance of a center of calcification
Leucopenia and abnormal liver function in travellers on malaria chemoprophylaxis
The joint commission: four key root causes loom large in sentinel event data
Treatment of vitiligo with topical 15% lactic acid solution in combination with ultra violet-A
Behaviour of dairy cows within three hours after feed supply: I. Influence of housing type and time elapsing after feed supply
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Management and control of patients with type 2 diabetes mellitus in Lebanon: results from the International Diabetes Management Practices Study (IDMPS)
The diet composition and nutritional knowledge of patients with anorexia nervosa
Physoporella croatica Herak, 1958 of the Slovak karst Anisian (Slovakia, the West Carpathians Mts.)
Bright lights, big noise. How effective are vehicle warning systems?
Ein Plesiosaurier-Rest mit Magensteinen aus mittlerem Lias von Quedlinburg
Incidence of Chlamydia trachomatis in patients with sterility
Monster soup: the microscope and Victorian fantasy
Preliminary tests with residual sprays against poultry lice
Duration of the life of plants in phylogeny

Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine


Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine



Journal of Pediatrics 111(1): 22-27



ISSN/ISBN: 0022-3476

PMID: 3110388

DOI: 10.1016/s0022-3476(87)80336-0

Thirty children vaccinated at 2 to 17 months of age with Haemophilus influenzae type b polysaccharide linked to a partially purified 40,000 dalton outer membrane protein of Neisseria meningitidis were revaccinated 10 to 14 months later with conventional H. influenzae type b polysaccharide vaccine. The geometric mean anti-type b antibody concentration before reimmunization was 0.68 micrograms/mL, and rose to 31 micrograms/mL in sera obtained 1 month later. The mean level after immunization was not significantly different than that in sera from 12 adults immunized with type b polysaccharide vaccine (51 micrograms/mL, P = 0.3), and was 10-fold higher than that of 13 control children immunized with type b polysaccharide for the first time (2.7 micrograms/mL, P less than 0.001). The IgG responses of the children first given conjugate vaccine and then conventional type b polysaccharide vaccine were of a similar magnitude as those in the immunized adults. Further, the children maintained high levels of serum antibody 6 to 8 months later. Ten other children vaccinated in infancy with conjugate vaccine, and again with conjugate vaccine 10 to 15 months later, showed similar antibody responses to those of the group given conjugate vaccine in infancy, and booster with conventional polysaccharide vaccine. Thus vaccination with H. influenzae type b polysaccharide-outer membrane protein conjugate vaccine primes the immune system to an IgG memory antibody response to either type b polysaccharide or conjugate vaccine. Post-booster sera from all children tested showed high titers of functional activity in a complement-mediated bactericidal assay. These data suggest that protection of most infants from type b Haemophilus disease may be achieved by a combination of immunization at 2 to 4 months of age with this conjugate vaccine, and reimmunization 1 year later with conjugate or conventional type b polysaccharide vaccine.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 040365702

Download citation: RISBibTeXText

Related references

Immunologic priming of infants with a single dose of haemophilus influenzae type b hib polysaccharide neisseria meningitidis outer membrane protein ps omp conjugate vaccine. Pediatric Research 21(4 Part 2): 334A, 1987

Dose-related immunogenicity of Haemophilus influenzae type b capsular polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. American Journal of Diseases of Children (1960) 145(7): 742-745, 1991

Dose-related immunogenicity of Haemophilus influenzae type b capsular polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. American Journal of Diseases of Children 145(7): 742-745, 1991

Distribution and excretion of capsular antigen after immunization with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. Journal of Infectious Diseases 161(3): 574-577, 1990

Immunogenicity of haemophilus influenzae type b capsular polysaccharide neisseria meningitidis outer membrane protein conjugate vaccine prp nomp in children 2 14 months of age. Clinical Research 39(1): 37A, 1991

Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet (British Edition) (8502): 299-302, 1986

Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet 2(8502): 299-302, 1986

Distribution and Excretion of Capsular Antigen after Immunization with Haemophilus influenzae Type b Polysaccharide-Neisseria meningitidis Outer Membrane Protein Conjugate Vaccine [With Discussion]. The Journal of Infectious Diseases 161(3): 574-577, 1990

Haemophilus influenzae type b hib capsular polysaccharide neisseria meningitidis outer membrane protein prp omp conjugate vaccine is highly immunogenic in young children less than 18 months of age. Pediatric Research 25(4 Part 2): 193A, 1989

Immunogenicity of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in 2- to 6-month-old infants. Pediatrics 80(2): 283-287, 1987

Immunogenicity of haemophilus influenzae type b hib polysaccharide ps neisseria meningitidis outer membrane protein conjugate vaccine ps omp in infants and young children. Pediatric Research 27(4 Part 2): 183A, 1990

The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. New England Journal of Medicine 324(25): 1767-1772, 1991

Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants. Pediatrics 86(1): 102-107, 1990

Long term follow up and response to a booster dose of haemophilus influenzae type b polysaccharide neisseria meningitidis outer membrane protein complex prp omp conjugate vaccine among children first immunized at 2 17 months of age. Pediatric Research 27(4 Part 2): 183A, 1990

Immunogenicity of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer membrane protein complex conjugate vaccine in infants and children with sickle cell disease. Pediatric Infectious Disease Journal 12(12): 1026-1027, 1993